Literature DB >> 19922462

Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.

Håkon Reikvam1, Kimberley J Hatfield, Anne M Oyan, Karl H Kalland, Astrid O Kittang, Oystein Bruserud.   

Abstract

OBJECTIVES: Angiogenesis seems important for both leukemogenesis and chemosensitivity in acute myelogenous leukemia (AML). Angiogenesis is regulated by the balance between pro- and antiangiogenic cytokines, which also indicates an important role of matrix metalloproteases (MMPs) and their natural inhibitors, tissue inhibitors of metalloproteases (TIMPs). We investigated the constitutive release of MMPs and TIMPs for a large group of consecutive AML patients.
METHODS: AML cells were cultured in vitro either alone or together with microvascular endothelial cells, and levels of MMPs and TIMPs were determined in culture supernatants.
RESULTS: AML cells showed constitutive release of several MMPs and TIMPs. For all patients, detectable MMP-10 release was observed, and most patients showed detectable release of at least one additional MMP, usually MMP-9 or MMP-2. A significant correlation was found between MMP-9 and TIMP-1 release and the release of several CCL and CXCL chemokines. MMP-9 release was higher for AML cells with monocytic differentiation corresponding to the FAB-subtype M4/M5 AML; it was mainly released in its inactive form, but endogenously active MMP-9 could be detected even in the presence of the constitutively released TIMP-1/2. Endothelial cells released relatively high levels of MMP-10, and these levels were further increased by coculture with AML cells. Patients achieving complete hematological remission after only one induction cycle showed relatively low constitutive MMP-2 release.
CONCLUSION: We conclude that primary human AML cells show constitutive release of both MMPs and TIMPs, and this release may be important for leukemogenesis and possibly also for chemosensitivity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19922462     DOI: 10.1111/j.1600-0609.2009.01382.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  17 in total

1.  The constitutive protease release by primary human acute myeloid leukemia cells.

Authors:  Maria Honnemyr; Øystein Bruserud; Annette K Brenner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-19       Impact factor: 4.553

2.  The anti-invasive activity of synthetic alkaloid ethoxyfagaronine on L1210 leukemia cells is mediated by down-regulation of plasminogen activators and MT1-MMP expression and activity.

Authors:  Jérôme Devy; Farid Ouchani; Christelle Oudot; Jean Jacques Helesbeux; Enguerran Vanquelef; Stéphanie Salesse; Fanja Rabenoelina; Siana Al-Khara; Isabelle Letinois; Olivier Duval; Laurent Martiny; Emmanuelle Charpentier
Journal:  Invest New Drugs       Date:  2010-03-28       Impact factor: 3.850

Review 3.  The progress of angiogenic factors in the development of leukemias.

Authors:  Yang Han; Xidi Wang; Bingping Wang; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2016-02

4.  Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids.

Authors:  Jesper Kolenda; Stine Skov Jensen; Charlotte Aaberg-Jessen; Karina Christensen; Claus Andersen; Nils Brünner; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-09-11       Impact factor: 4.130

5.  Endocan, a potential prognostic and diagnostic biomarker of acute leukemia.

Authors:  Zhe Xu; Sumei Zhang; Qing Zhou; Yuan Wang; Ruixiang Xia
Journal:  Mol Cell Biochem       Date:  2014-06-17       Impact factor: 3.396

6.  Heroin Seeking and Extinction From Seeking Activate Matrix Metalloproteinases at Synapses on Distinct Subpopulations of Accumbens Cells.

Authors:  Vivian C Chioma; Anna Kruyer; Ana-Clara Bobadilla; Ariana Angelis; Zachary Ellison; Ritchy Hodebourg; Michael D Scofield; Peter W Kalivas
Journal:  Biol Psychiatry       Date:  2020-12-09       Impact factor: 13.382

Review 7.  The possible diagnostic and prognostic use of systemic chemokine profiles in clinical medicine—the experience in acute myeloid leukemia from disease development and diagnosis via conventional chemotherapy to allogeneic stem cell transplantation.

Authors:  Håkon Reikvam; Hanne Fredly; Astrid Olsnes Kittang; Oystein Bruserud
Journal:  Toxins (Basel)       Date:  2013-02-18       Impact factor: 4.546

8.  Involvement of CD11b integrin in the alteration of metabolic factors after phorbol ester stimulation of human myeloid leukemia cells.

Authors:  Katharina Mandel; Anna Otte; Ralf Hass
Journal:  Cell Commun Signal       Date:  2012-07-11       Impact factor: 5.712

9.  Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins.

Authors:  Saran Feng; Jiannong Cen; Yihong Huang; Hongjie Shen; Li Yao; Yuanyuan Wang; Zixing Chen
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

10.  Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells.

Authors:  Håkon Reikvam; Ina Nepstad; Øystein Bruserud; Kimberley Joanne Hatfield
Journal:  Oncotarget       Date:  2013-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.